# US 2004/0001867 A1 · Vectors for molecule delivery to CD11b expressing cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0001867 A1
- Document ID: US20040001867A1
- Status: Published application
- Kind: A1
- Application number: 10/387,486
- Filed: 2003-03-14
- Published: 2004-01-01
- Earliest claimed: 2000-09-15
- Inventors: Claude Leclerc; Pierre Guermonprez; Daniel Ladant; Nicole Guiso; Nadia Khelef; Cecile Bauche; Catherine Fayolle; Mohammed El-Azami El-Idrissi
- Web page: https://patentgrep.com/patent/US20040001867A1

## CPC

- A61K 39/099: {Bordetella}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/88: Lyases (4.)
- C12N 15/85: for animal cells
- C12Y 406/01001: Aodenylate cyclase (4.6.1.1)
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.

## Claims

### Claim 1

Use of Bordetella species adenylcyclase in the manufacturing of a proteinaceous vector for targeting a molecule of interest specifically to CD11b expressing cells.

### Claim 2

Use of a Bordetella adenylcyclase wherein said adenylcyclase is modified by insertion of a molecule of interest for the preparation of a composition for the targeting of said molecule to CD11b expressing cells.

### Claim 3 (depends on 2)

The use according to claim 2 wherein said Bordetella species adenylcyclase is a fragment of the Bordetella adenylcyclase toxin, wherein said fragment is capable of binding the CD1 b receptor.

### Claim 4 (depends on 3)

The use according to claim 3, wherein said fragment of the Bordetella adenylcyclase toxin capable of binding the CD11b receptor is the Bordetella adenylcyclase toxin lacking all or part of its N-terminal catalytic domain.

### Claim 5 (depends on 4)

The use according to claim 4, wherein said fragment of the Bordetella adenylcyclase toxin capable of binding the CD11b receptor is the Bordetella pertussis adenylcyclase toxin lacking all or part of residues 1-373.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The use according to anyone of claims 1 to 5 wherein the targeting of said molecule of interest is effective in vivo.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The use according to any one of claims 1 to 6 wherein the molecule of interest is specifically targeted and translocated in the cytosol of CD11b expressing cells.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The use according to any one of claims 1 to 7 wherein said CD11b expressing cells are dendritic cells and more preferably myeloid dendritic cells.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The use according to any one of claims 1 to 8 wherein said CD11b expressing cells are neutrophils.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The use according to any one of claims 1 to 9 wherein the adenylcyclase is a genetically modified Bordetella species adenylcyclase.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The use according to any one of claims 1 to 10 wherein the adenylcyclase is a non toxic form.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The use according to any one of claims 1 to 11 wherein the adenylcyclase is from Bordetella pertussis.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The use according to any one of claims 1 to 12 wherein the molecule of interest is selected in the group comprising: peptides, glycopeptides, lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids and chemicals.

### Claim 14 (depends on 13)

The use according to claim 13 wherein the molecule of interest is an antigen.

### Claim 15 (depends on 13)

The use according to claim 13 wherein the molecule of interest comprises an epitope.

### Claim 16 (depends on 15)

The use according to claim 15, wherein the molecule of interest is a heterologous peptide fused to the N-terminal extremity of a genetically modified Bordetella adenylcyclase lacking all or part of its N-terminal catalytic domain, and more preferably Bordetella pertussis adenylcyclase lacking residues 1-373.

### Claim 17 (depends on 14)

The use according to claim 14 wherein said antigen is selected from the group consisting of an intracellular bacterial cell antigen, a tumoral cell antigen, a viral antigen, a fungus antigen or a parasite cell antigen.

### Claim 18 (depends on 17)

The use according to claim 17 wherein said antigen is selected from the group consisting of: a poliovirus antigen, an HIV virus antigen, an influenza virus antigen, a choriomeningitis virus epitope, a tumor antigen.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use according to any one of claims 1 to 13 wherein the molecule of interest is a drug chemically or genetically coupled to the adenylcyclase toxin.

### Claim 20 (depends on 19)

The use according to claim 19, wherein said drug is chemically coupled by means of a disulfide bond to a genetically inserted cysteine residue located in the catalytic domain of said adenylcyclase.

### Claim 21 (depends on 19, 20)

The use according to any one of claim 19 or 20, wherein the drug is an anti-inflammatory drug.

### Claim 22

An immunogenic composition formulated for administration in an animal or a human host characterized in that it comprises a Bordetella adenylcyclase which comprises an antigen inserted in the catalytic domain.

### Claim 23

A pharmaceutical composition for administration in a human or an animal formulated for targeting a molecule of interest specifically to CD11b expressing cells characterized in that said molecule of interest is coupled to a Bordetella species adenylcyclase.

### Claim 24 (depends on 22, 23)

The immunogenic or pharmaceutical composition according to claim 22 or 23, wherein the adenylcyclase is a genetically modified adenylcyclase.

### Claim 25 (depends on 24)

The immunogenic or pharmaceutical composition according to claim 24, wherein the genetically modified adenylcyclase is able to translocate the molecule of interest specifically in the cytosol of CD11 b expressing cells.

### Claim 26 (depends on 25)

The immunogenic or pharmaceutical composition according to claim 25, wherein said genetically modified adenylcyclase is a Bordetella adenylcyclase lacking all or part of its catalytic N-terminal domain.

### Claim 27 (depends on 25)

The immunogenic or pharmaceutical composition according to claim 25, wherein said genetically modified adenylcyclase is the Bordetella pertussis adenylcyclase lacking residues 1-373.

### Claim 28 (depends on 24, 25)

The immunogenic or pharmaceutical composition according to any one of claim 24 or 25, wherein said genetically modified adenylcyclase comprises one or more cysteine residue(s) inserted within the catalytic domain at a permissive site.

### Claim 29 (depends on 22, 23, 24, 25, 26, 27, 28)

The immunogenic or pharmaceutical composition according to any one of claims 22 to 28, wherein said CD11b expressing cells are dendritic cells and more preferably myeloid dendritic cells.

### Claim 30 (depends on 22, 23, 24, 25, 26, 27, 28)

The immunogenic or pharmaceutical composition according to any one of claims 22 to 28, wherein said CD11b expressing cells are neutrophils.

### Claim 31 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30)

The pharmaceutical or immunogenic composition according to claims 22 to 30, wherein the molecule of interest is selected in the group comprising: peptides, glycopeptides, lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids and chemicals.

### Claim 32 (depends on 22, 23, 24, 25, 26, 27, 28, 29)

The pharmaceutical or immunogenic composition according to claims 22 to 29, wherein said composition comprises a nucleic acid construction encoding the Bordetella species adenylate cyclase coupled to a molecule of interest.

### Claim 33 (depends on 31)

The pharmaceutical or immunogenic composition according to claim 31, wherein the molecule of interest is a drug.

### Claim 34 (depends on 33)

The pharmaceutical composition according to claim 33, wherein the drug is an anti-inflammatory drug.

### Claim 35 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The pharmaceutical or immunogenic composition according to claims 22 to 31, wherein the molecule of interest is an antigen.

### Claim 36 (depends on 35)

The immunogenic or pharmaceutical composition according to claim 35 wherein the antigen is selected from the group consisting of: an intracellular bacterial cell antigen, a tumoral cell antigen, a viral antigen, a fungus antigen or a parasite cell antigen.

### Claim 37 (depends on 36)

The immunogenic or pharmaceutical composition according to claim 36 wherein the antigen is selected from the group consisting of; a poliovirus antigen, an HIV virus, an influenza virus antigen, a choriomeningitis virus antigen, a tumor antigen.

### Claim 38 (depends on 35, 36, 37)

The immunogenic or pharmaceutical composition according to any one of claims 35 to 37, wherein said antigen is fused to the N-terminal part of a genetically modified Bordetella adenylcyclase lacking its N-terminal catalytic domain.

### Claim 39 (depends on 35, 36, 37, 38)

The immunogenic or pharmaceutical composition according to any one of claims 35 to 38, wherein said antigen is fused to the genetically modified Bordetella pertussis adenylcyclase lacking residues 1-373.

### Claim 40 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The immunogenic or pharmaceutical composition according to any one of claims 22 to 39 wherein said composition is formulated for intravenous administration and especially is devoid of priming adjuvants.

### Claim 41 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The immunogenic composition according to any one of claims 22 to 40, wherein said immunogenic composition is capable of inducing or stimulating an immune response involving specifically dendritic cells.

### Claim 42 (depends on 35, 36, 37, 38, 39)

Use of the immunogenic or pharmaceutical composition according to any one of claims 35 to 39 for the preparation of a vaccine or an immunotherapeutic composition.

### Claim 43

A proteinaceous vector for delivery of a molecule of interest, specifically to CD11b expressing cells, characterized in that said vector comprises a recombinant Bordetella species adenylcyclase coupled to said molecule of interest.

### Claim 44 (depends on 43)

The proteinaceous vector according to claim 43 wherein said vector is also able to deliver the molecule of interest specifically in the cytosol of CD11b expressing cells.

### Claim 45 (depends on 43, 44)

The proteinaceous vector according to claim 43 or 44 wherein said CD11b expressing cells are dendritic cells and more preferably myeloid dendritic cells.

### Claim 46 (depends on 43, 44)

The proteinaceous vector according to claim 43 or 44 wherein said CD11b expressing cells are neutrophils.

### Claim 47 (depends on 43, 44, 45, 46)

The proteinaceous vector according to any one of claims 43 to 46 wherein the adenylcyclase is a genetically modified adenylcyclase.

### Claim 48 (depends on 47)

The proteinaceous vector according to claim 47, wherein said genetically modified adenylcyclase is devoid of native cysteine residue but contains genetically inserted cysteine residue(s) at permissive site(s) within the catalytic domain.

### Claim 49 (depends on 47, 48)

The proteinaceous vector according to any one of claim 47 or 48 wherein the adenylcyclase is a non toxic adenylcyclase.

### Claim 50 (depends on 47, 48, 49)

The proteinaceous vector according to any one of claims 47 to 49, wherein the genetically modified adenylcyclase is a Bordetella adenylclase lacking all or part of its N-terminal catalytic domain.

### Claim 51 (depends on 43, 44, 45, 46, 47, 48, 49, 50)

The proteinaceous vector according to any one of claims 43 to 50 wherein the adenylcyclase is from Bordetella pertussis.

### Claim 52 (depends on 51)

The proteinaceous vector according to claim 51, wherein said recombinant adenylcyclase is the Bordetella pertussis adenylcyclase lacking residues 1-373.

### Claim 53 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The proteinaceous vector according to claims 43 to 52, wherein said molecule of interest is selected in the group comprising: peptides, glycopeptides, lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids and chemicals.

### Claim 54 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The proteinaceous vector according to any one of claims 43 to 53, wherein said molecule of interest is a drug chemically or genetically coupled to said adenylcyclase.

### Claim 55 (depends on 54)

The proteinaceous vector according to claim 54, wherein the molecule of interest is an epitope.

### Claim 56 (depends on 54, 55)

The proteinaceous vector according to any one of claim 54 or 55, wherein said molecule of interest is an epitope chemically coupled to a genetically modified adenylcyclase devoid of native cysteine residue but containing genetically inserted cysteine residue(s) at permissive site(s) within its catalytic domain.
